Sunbelt Securities Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 4.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,626 shares of the medical research company’s stock after purchasing an additional 198 shares during the quarter. Sunbelt Securities Inc.’s holdings in Amgen were worth $1,043,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the business. Culbertson A N & Co Inc increased its holdings in Amgen by 19.8% in the 3rd quarter. Culbertson A N & Co Inc now owns 1,450 shares of the medical research company’s stock valued at $326,000 after buying an additional 240 shares during the period. Mather Group LLC. increased its holdings in Amgen by 2.3% in the 2nd quarter. Mather Group LLC. now owns 4,097 shares of the medical research company’s stock valued at $997,000 after buying an additional 91 shares during the period. Schmidt P J Investment Management Inc. bought a new position in Amgen in the 2nd quarter valued at about $235,000. NewSquare Capital LLC increased its holdings in Amgen by 7.3% in the 3rd quarter. NewSquare Capital LLC now owns 18,425 shares of the medical research company’s stock valued at $4,153,000 after buying an additional 1,249 shares during the period. Finally, Brown Advisory Inc. increased its holdings in Amgen by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 490,102 shares of the medical research company’s stock valued at $119,241,000 after buying an additional 26,471 shares during the period. Institutional investors and hedge funds own 75.53% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have commented on AMGN shares. Royal Bank of Canada decreased their target price on shares of Amgen from $268.00 to $258.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 1st. Wells Fargo & Company raised shares of Amgen from an “equal weight” rating to an “overweight” rating and decreased their price target for the company from $275.00 to $265.00 in a report on Monday. Barclays decreased their price target on shares of Amgen from $240.00 to $230.00 and set an “underweight” rating on the stock in a report on Wednesday, February 1st. SVB Leerink decreased their price target on shares of Amgen from $282.00 to $267.00 and set a “market perform” rating on the stock in a report on Thursday, February 2nd. Finally, Credit Suisse Group decreased their price target on shares of Amgen from $240.00 to $220.00 and set an “underperform” rating on the stock in a report on Wednesday, February 1st. Four analysts have rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $251.44.
Amgen Trading Up 1.9 %
Amgen (NASDAQ:AMGN – Get Rating) last issued its quarterly earnings results on Tuesday, February 7th. The medical research company reported $4.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.05. The firm had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.77 billion. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The company’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.36 EPS. As a group, research analysts predict that Amgen Inc. will post 17.72 earnings per share for the current year.
Amgen Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Stockholders of record on Thursday, May 18th will be given a $2.13 dividend. The ex-dividend date is Wednesday, May 17th. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.63%. Amgen’s dividend payout ratio (DPR) is currently 70.36%.
About Amgen
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Featured Articles
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
